NCT05043831 is a NA clinical trial of DSLT in Glaucoma, Open-Angle, sponsored by BelkinVision.

Who is sponsoring NCT05043831?

NCT05043831 is sponsored by BelkinVision.

What drugs are being tested in NCT05043831?

Interventions in NCT05043831: DSLT.

What condition does NCT05043831 study?

NCT05043831 studies Glaucoma, Open-Angle, Ocular Hypertension.

Is NCT05043831 still recruiting?

NCT05043831 is currently withdrawn. Last updated 12 May 2023.

Last reviewed 2023-05-12 · How we verify

NCT05043831

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population The Zhuiguang Trial

Withdrawn NA Last updated 12 May 2023

What this trial tests

NA trial testing DSLT in Glaucoma, Open-Angle. Withdrawn.

Timeline

15 October 2021

Primary endpoint
15 January 2023

15 April 2023

Quick facts

Lead sponsor	BelkinVision
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	15 October 2021
Primary completion	15 January 2023
Estimated completion	15 April 2023

Drugs / interventions tested

DSLT

Conditions studied

Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

BelkinVision

Who can join

40 and older, any sex, with Glaucoma, Open-Angle or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the effectiveness (Intra-Ocular Pressure lowering) and safety of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese subjects with Primary Open Angle Glaucoma or Ocular Hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glaucoma, Open-Angle

Currently open trials in the same condition.

NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting

Other BelkinVision trials

Trials by the same sponsor.

NCT05271734 — Evaluation of the Compatibility of Different Eye Lid Retractors to the Direct Selective Laser Trabeculoplasty (DSLT) Pro · NA · completed
NCT04758598 — The Effects of DSLT and SLT on the Corneal Endothelium: A GLAUrious Trial Sub-Study · NA · completed
NCT03750201 — A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05043831 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BelkinVision
Last refreshed: 12 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05043831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing